S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
[BREAKING] New "Living Software" to Revolutionize Warfare (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Free A.I. Trade Alerts. Up to 15 opportunities a day. (Ad)
Vatican singles out bishops in urging reflective not reactive social media use
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
NASDAQ:AGLE

Aeglea BioTherapeutics (AGLE) Stock Forecast, Price & News

$0.14
0.00 (-3.43%)
(As of 05/26/2023 08:46 PM ET)
Compare
Today's Range
$0.14
$0.14
50-Day Range
$0.14
$0.33
52-Week Range
$0.13
$1.64
Volume
249,900 shs
Average Volume
614,817 shs
Market Capitalization
$8.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.88

Aeglea BioTherapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
1,286.8% Upside
$1.88 Price Target
Short Interest
Healthy
0.66% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Aeglea BioTherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.47) to ($0.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars


AGLE stock logo

About Aeglea BioTherapeutics (NASDAQ:AGLE) Stock

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Stock News Headlines

Free SMS Trade Alerts. Up to 15 opportunities a day.
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
10-Q: AEGLEA BIOTHERAPEUTICS, INC.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
See More Headlines
Receive AGLE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aeglea BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGLE Company Calendar

Last Earnings
3/02/2023
Today
5/29/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AGLE
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.88
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+1,286.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-83,820,000.00
Net Margins
-6,678.20%
Pretax Margin
-6,692.96%

Debt

Sales & Book Value

Annual Sales
$2.33 million
Book Value
$0.51 per share

Miscellaneous

Free Float
63,302,000
Market Cap
$8.84 million
Optionable
Optionable
Beta
1.75

Key Executives

  • Jeffrey M. Goldberg
    President, Chief Executive Officer & Director
  • Jonathan D. AlspaughJonathan D. Alspaugh
    Chief Financial & Accounting Officer
  • Scott W. Rowlinson
    Vice President-Research
  • Cortney Caudill
    Chief Product Officer
  • Eric Bradford
    Chief Development Officer













AGLE Stock - Frequently Asked Questions

Should I buy or sell Aeglea BioTherapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last twelve months. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AGLE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AGLE, but not buy additional shares or sell existing shares.
View AGLE analyst ratings
or view top-rated stocks.

What is Aeglea BioTherapeutics' stock price forecast for 2023?

6 analysts have issued 1-year price objectives for Aeglea BioTherapeutics' shares. Their AGLE share price forecasts range from $1.00 to $3.00. On average, they anticipate the company's stock price to reach $1.88 in the next year. This suggests a possible upside of 1,286.8% from the stock's current price.
View analysts price targets for AGLE
or view top-rated stocks among Wall Street analysts.

How have AGLE shares performed in 2023?

Aeglea BioTherapeutics' stock was trading at $0.4499 at the beginning of 2023. Since then, AGLE stock has decreased by 69.9% and is now trading at $0.1352.
View the best growth stocks for 2023 here
.

When is Aeglea BioTherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our AGLE earnings forecast
.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) released its quarterly earnings results on Thursday, March, 2nd. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.02. The biotechnology company had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.17 million. Aeglea BioTherapeutics had a negative net margin of 6,678.20% and a negative trailing twelve-month return on equity of 132.05%.

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics Chief Executive Officer Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among the company's employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aeglea BioTherapeutics own?
When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an initial public offering (IPO) on Thursday, April 7th 2016. The company issued 3,500,000 shares at $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sphera Funds Management LTD. (0.99%), Two Sigma Investments LP (0.49%), Carlyle Group Inc. (0.37%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Anthony G Quinn, Armen Shanafelt, Jonathan Alspaugh, Jr Michael Conick Hanley and Marcio Souza.
View institutional ownership trends
.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $0.14.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics (NASDAQ:AGLE) has a market capitalization of $8.84 million and generates $2.33 million in revenue each year. The biotechnology company earns $-83,820,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Aeglea BioTherapeutics have?

The company employs 101 workers across the globe.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The official website for the company is www.aegleabio.com. The biotechnology company can be reached via phone at (512) 942-2935, via email at investors@aegleabio.com, or via fax at 512-872-5121.

This page (NASDAQ:AGLE) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -